Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia

Leukemia Research

Volumn 38, Issue 5, 2014, Pages 564-568

  Pierceall, William E ^a   Lena, Ryan J ^a   Medeiros, Bruno C ^b   Blake, Noel ^a   Doykan, Camille ^a   Elashoff, Michael ^a   Cardone, Michael H ^a   Walter, Roland B ^c,d  

^a Eutropics Pharmaceuticals   (United States)

^b STANFORD UNIVERSITY   (United States)

^c USA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

AML; Biomarker; Gemtuzumab ozogamicin; HDAC inhibitors; Personalized medicine

Indexed keywords

AML; BIOMARKER; GEMTUZUMAB OZOGAMICIN; HDAC INHIBITORS; PERSONALIZED MEDICINE;

AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA, MYELOID, ACUTE; LOGISTIC MODELS; MALE; MIDDLE AGED; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84898882005     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.02.007     Document Type: Article

References (30)

1. SEER Cancer statistics review, 1975-2010 2013, National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2010/, N. Howlader, A.M. Noone, M. Krapcho (Eds.).
2. Appelbaum F.R., Gundacker H., Head D.R., et al. Age and acute myeloid leukemia. Blood 2006, 107:3481-3485.
3. Döhner H., Estey E.H., Amadori S., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
4. NCCN clinical practice guidelines in oncology (NCCN guidelines™) Acute myeloid leukemia. Version 1 2012, Available from: www.nccn.org.
5. Walter R.B., Appelbaum F.R., Estey E.H., Bernstein I.D. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 2012, 119:6198-6208.
6. Cowan A.J., Laszlo G.S., Estey E.H., Walter R.B. Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. Front Biosci 2013, 18:1311-1334.
7. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5:769-784.
8. ten Cate B., Samplonius D.F., Bijma T., et al. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells. Leukemia 2007, 21:248-252.
9. Walter R.B., Medeiros B.C., Powell B.L., Schiffer C.A., Appelbaum F.R., Estey E.H. Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia. Haematologica 2012, 97:739-742.
10. Ni Chonghaile T., Sarosiek K.A., Vo T.T., et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011, 334:1129-1133.
11. Vo T.T., Ryan J., Carrasco R., et al. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 2012, 151:344-355.
12. Pierceall W.E., Kornblau S.M., Carlson N.E., et al. BH3 Profiling discriminates response to cytarabine-based treatment of acute myeloid leukemia. Mol Cancer Ther 2013, 12:2940-2949.
13. Letai A. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 2008, 8:121-132.
14. Certo M., Del Gaizo Moore V., Nishino M., et al. Mitochondria pried by death signals determine cellular addiction to antiapoptotic Bcl-2 family members. Cancer Cell 2006, 9:351-365.
15. Haag P., Victorsson K., Lindberg M.L., Kanter L., Lewensohn R., Stenke L. Deficient activation of Bax and Bak confers resistance to gemtuzumab ozogamicin-induced apoptotoic cell death in AML. Exp Hematol 2009, 37:755-766.
16. Rosato R.R., Almenara J.A., Kolla S.S., et al. Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions. Mol Cancer Ther 2007, 6:692-702.
17. Dasmahapatra G., Yerram N., Dai Y., Dent P., Grant S. Synergistic intereactions between vorinostat and sorafenib in chronic myelogenous leukemic cells involve Mcl-1 and p21CIP1 down-regulation. Clin Cancer Res 2007, 13:4280-4290.
18. Cheson B.D., Bennett J.M., Kopecky K.J., et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003, 21:4642-4649.
19. Walter R.B., Othus M., Borthakur G., et al. Quantitative effect of age in predicting empirically-defined treatment-related mortality and resistance in newly diagnosed AML: case against age alone as primary determinant of treatment assignment. Blood 2010, 116:904. Abstract #2191.
20. Ryan J.A., Brunelle J.K., Letai A. Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes. Proc Natl Acad Sci USA 2010, 107:12895-12900.
21. Richard D.J., Lena R., Bannister T., et al. Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker. Bioorg Med Chem 2013, 21:6642-6649.
22. Davids M.S., Letai A. ABT-199: taking dead aim at BCL-2. Cancer Cell 2013, 23:139-141.
23. Prokop A., Wrasidio W., Lode H., et al. Induction of apoptosis by enediyne antibiotic calicheamicin thetall proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner. Oncogene 2013, 22:9107-9120.
24. Green S.R., Choudary A.K., Fleming I.N. Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types. Br J Cancer 2010, 103:1391-1399.
25. Barbone D., Cheung P., Battula S., et al. Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression. PLoS ONE 2012, 7:e52753.
26. Kaufmann S.H., Karp J.E., Svingen P.A., et al. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 1998, 91:991-1000.
27. Fayad L., Offner F., Smith M.R., et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol 2013, 31:573-583.
28. Kantarjian H., Thomas D., Jorgensen J., et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 2012, 13:403-411.
29. Kremer K.N., Peterson K.L., Schneider P.A., et al. CXCR4 chemokine receptor mechanistic signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak. J Biol Chem 2013, 288:22899-22914.
30. Zhou L., Ruvolo V.R., McQueen T., et al. HDAC inhibition by SNDX-275 (entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML. Leukemia 2013, 27:1358-1368.